EODData

MEMBERSHIP REGISTER LOG IN

FRA, NV3P: NANOVIRICIDES NEW DL-01

02 Oct 2025
LAST:

1.170

CHANGE:
 0.04		OPEN:
1.140		HIGH:
1.170		ASK:
0.000		VOLUME:
3.3K
CHG(%):
3.54		PREV:
1.130		LOW:
1.140		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
02 Oct 251.1401.1701.1401.1703.3K
01 Oct 251.1301.1301.1301.1300
30 Sep 251.1201.1201.1201.1200
29 Sep 251.1301.1301.1301.1303.3K
26 Sep 251.1101.1401.1101.1403.3K
25 Sep 251.1301.1301.1301.1303.3K
24 Sep 251.1401.1401.1401.1403.3K
23 Sep 251.1401.1401.1401.1403.3K
22 Sep 251.1701.1701.1701.1703.3K
19 Sep 251.1201.1201.1201.1203.3K

COMPANY PROFILE

Name:NANOVIRICIDES NEW DL-01
About:NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
Sector:Healthcare
Industry:Biotechnology
Address:1 Controls Drive, Shelton, CT, United States, 06484
Website:https://www.nanoviricides.com
ISIN:US6300873022
LEI:5493003CK9Y2H0OORR73

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:1.14
MA10:1.14
MA20:1.14
MA50:1.21
MA100:1.21
MA200:1.17
STO9:100.00
STO14:100.00
RSI14:52.38
MTM14:0.02
ROC14:0.02
ATR:0.02
Week High:1.17
Week Low:1.11
Month High:1.19
Month Low:1.09
Year High:1.70
Year Low:0.80
Volatility:42.62

RECENT SPLITS

Date Ratio
10 Sep 20131-3.5